BR112013008695A2 - compostos de 7-hidróxi-pirazol[1,5-a] pirimidina e seu uso como antagonistas do receptor ccr2 - Google Patents

compostos de 7-hidróxi-pirazol[1,5-a] pirimidina e seu uso como antagonistas do receptor ccr2

Info

Publication number
BR112013008695A2
BR112013008695A2 BR112013008695A BR112013008695A BR112013008695A2 BR 112013008695 A2 BR112013008695 A2 BR 112013008695A2 BR 112013008695 A BR112013008695 A BR 112013008695A BR 112013008695 A BR112013008695 A BR 112013008695A BR 112013008695 A2 BR112013008695 A2 BR 112013008695A2
Authority
BR
Brazil
Prior art keywords
pyrazolo
hydroxy
receptor antagonists
pyrimidine compounds
ccr2 receptor
Prior art date
Application number
BR112013008695A
Other languages
English (en)
Inventor
David Mountford
Edward Daniel Savory
Iain Simpson
Joe William Boyd
Michael Higginbottom
Paul Meo
Original Assignee
Proximagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1016221.2A external-priority patent/GB201016221D0/en
Priority claimed from GBGB1113971.4A external-priority patent/GB201113971D0/en
Application filed by Proximagen Ltd filed Critical Proximagen Ltd
Publication of BR112013008695A2 publication Critical patent/BR112013008695A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112013008695A 2010-09-27 2011-09-26 compostos de 7-hidróxi-pirazol[1,5-a] pirimidina e seu uso como antagonistas do receptor ccr2 BR112013008695A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1016221.2A GB201016221D0 (en) 2010-09-27 2010-09-27 New compounds
GBGB1113971.4A GB201113971D0 (en) 2011-08-15 2011-08-15 New compounds ii
PCT/EP2011/066697 WO2012041817A1 (en) 2010-09-27 2011-09-26 7-hydroxy-pyrazolo[1,5-a] pyrimidine compounds and their use as ccr2 receptor antagonists

Publications (1)

Publication Number Publication Date
BR112013008695A2 true BR112013008695A2 (pt) 2016-06-21

Family

ID=45891994

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013008695A BR112013008695A2 (pt) 2010-09-27 2011-09-26 compostos de 7-hidróxi-pirazol[1,5-a] pirimidina e seu uso como antagonistas do receptor ccr2

Country Status (10)

Country Link
US (1) US20130252951A1 (pt)
EP (1) EP2621928A1 (pt)
JP (1) JP2013538838A (pt)
CN (1) CN103328479A (pt)
AU (1) AU2011310713A1 (pt)
BR (1) BR112013008695A2 (pt)
CA (1) CA2811934A1 (pt)
IL (1) IL225299A0 (pt)
SG (1) SG189086A1 (pt)
WO (1) WO2012041817A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015022545A2 (pt) * 2013-03-13 2017-07-18 Constellation Pharmaceuticals Inc compostos de pirazolo e os usos disso
WO2015036563A1 (de) 2013-09-16 2015-03-19 Bayer Pharma Aktiengesellschaft Disubstituierte trifluormethylpyrimidinone und ihre verwendung als ccr2 antagonisten
WO2016104777A1 (ja) * 2014-12-26 2016-06-30 国立大学法人九州大学 がんの処置のための方法
WO2016113205A1 (de) 2015-01-13 2016-07-21 Bayer Pharma Aktiengesellschaft Substituierte pentafluorethylpyrimidinone und ihre verwendung
MX2021014356A (es) * 2016-11-23 2022-11-24 Chemocentryx Inc Metodo para tratar glomeruloesclerosis segmentaria focal.
SG11202002218VA (en) 2017-09-15 2020-04-29 Aduro Biotech Inc Pyrazolopyrimidinone compounds and uses thereof
AU2018347361A1 (en) * 2017-10-11 2020-04-30 Chemocentryx, Inc. Treatment of focal segmental glomerulosclerosis with CCR2 antagonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3338292A1 (de) * 1983-10-21 1985-05-02 Basf Ag, 6700 Ludwigshafen 7-amino-azolo(1,5-a)-pyrimidine und diese enthaltende fungizide
WO1992006096A1 (en) 1990-10-09 1992-04-16 Otsuka Pharmaceutical Co., Ltd. Pyrimidine derivative, production thereof, and androgen inhibitor
FR2687676B1 (fr) * 1992-02-24 1994-07-08 Union Pharma Scient Appl Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii; leurs procedes de preparation, compositions pharmaceutiques les contenant.
FR2687677B1 (fr) 1992-02-24 1996-10-11 Union Pharma Scient Appl Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant.
WO1998054093A1 (en) * 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
US7262199B2 (en) 2002-12-11 2007-08-28 Merck & Co., Inc. Tyrosine kinase inhibitors
US20100075993A1 (en) * 2005-06-30 2010-03-25 Drexel University Small molecule inhibitors against west nile virus replication
WO2008116898A1 (en) * 2007-03-28 2008-10-02 Biovitrum Ab (Publ) Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase
EP2219646A4 (en) * 2007-12-21 2010-12-22 Univ Rochester METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
KR20100133385A (ko) * 2008-02-26 2010-12-21 노파르티스 아게 Ｃｘｃｒ2의 억제제로서의 헤테로시클릭 화합물
WO2011114148A1 (en) * 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
WO2011135491A1 (en) * 2010-04-26 2011-11-03 Basf Se Herbicidal azolopyrimidines
EP2566333A4 (en) * 2010-05-07 2014-04-02 Univ Leland Stanford Junior IDENTIFICATION OF STABILIZERS OF MULTIMEDER PROTEINS

Also Published As

Publication number Publication date
WO2012041817A1 (en) 2012-04-05
JP2013538838A (ja) 2013-10-17
US20130252951A1 (en) 2013-09-26
EP2621928A1 (en) 2013-08-07
CN103328479A (zh) 2013-09-25
IL225299A0 (en) 2013-06-27
SG189086A1 (en) 2013-05-31
AU2011310713A1 (en) 2013-04-11
CA2811934A1 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
BR112012029437A2 (pt) derivados de pirrolo[2,3-b]pirazina-7-carboxamida e seu uso como inibidores de jak e syk
HRP20190361T1 (hr) Derivati triazolo[4,5-d]pirimidina kao antagonisti cb2 receptora
BRPI0813831A2 (pt) Compostos de heteroarila bicíclica e seu uso como inibidores de quinase
BR112013016030A2 (pt) compostos e seu uso como inibidores de bace
BRPI0919844A2 (pt) compostos de azaindazol como antagonistas do receptor ccr1
BRPI1015145A2 (pt) derivados de tiazol e seu uso como receptores antagonistas de p2y12
BR112013011520A2 (pt) pirazolo piridinas e pirazolo piridinas e seu uso como inibidores de tyk2
BR112013008695A2 (pt) compostos de 7-hidróxi-pirazol[1,5-a] pirimidina e seu uso como antagonistas do receptor ccr2
BRPI0920448A2 (pt) compostos spiro-oxindol e seu uso como agentes terapêuticos
BRPI0821141A2 (pt) Derivados de heteroarila como antagonistas do receptor de orexina
BRPI0909157A2 (pt) compostos heterocíclicos como antagonistas de receptores de adenosina
CR10249A (es) Compuestos de amino- pirimidina 2,6-sistituidos -4-monosustituidos como antagonistas del receptor de prostaglandina d2
BRPI0908225A2 (pt) derivados de piridazina e seu uso como agentes terapêuticos
BRPI0817245A2 (pt) Derivados e quinolina como antagonistas receptores de 5ht5a
BRPI0717023A2 (pt) Tiazol pirazolopirimidina como antagonistas do receptor de crf1
BRPI0717937A2 (pt) Compostos de pirazona como antagonistas do receptor mineralocorticóide
BRPI1008850A2 (pt) [1,2,4]triazolo[1,5-a]piridinas como inibidores de quinase
BR112012008044A2 (pt) pteridinas e seu uso como agroquímicos
BRPI0913885A2 (pt) Tiadiazoliloxifenilamidinas e seus uso como fungicidas
CO6930360A2 (es) Derivados de [1,2,3]triazolo[4,5-d]pirimidina como agonistas preferentes del receptor de canabinoides 2
BRPI0817061A2 (pt) Derivados de pirrolidinilalquilisoquinolinona e -isoindolinona como antagonistas de histamina-3
BRPI0808846A2 (pt) fenoxifenilamidinas 3-substituídas e seu uso como fungicidas
BRPI0922303A2 (pt) arilciclo-hexiléteres de di-hidrotetra-azabenzoazulenos para o uso como antagonistas do receptor de vasopressina v1a
CO6781555A2 (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación
BRPI0921669A2 (pt) piperazina de arila e seu uso como antagonistas alfa 2c

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.